Genetic Testing Market Size to Rise USD 17.30 Bn By 2032

01 Mar 2024

Share :

Table of Content

1. Market Overview 2. Regional Snapshot 3. Genetic Testing Market Report Scope 4. Market Dynamics 5. Recent Developments 6. Key Market Players

The global genetic testing market size surpassed USD 8.20 billion in 2022 and is expected to rise around USD 17.30 billion by 2032, poised to grow at a CAGR of 7.80% from 2023 to 2032.

Market Overview

A medical practice called genetic testing looks for alterations in proteins, chromosomes, or genes. It can ascertain a person's risk of contracting or passing on a genetic ailment and confirm or rule out a suspected genetic condition. More than 77,000 genetic tests are already available, and more are being created. Chromosome tests examine entire chromosomes to discover significant genetic alterations; gene testing examines DNA sequences to find mutations that raise the chance of a genetic disorder, and protein studies look for anomalies.

Doctors should distinguish genetic testing that is "research only" and clinically available. Clinical testing is carried out by labs that have obtained the federally required CLIA certification; research testing is typically unnecessary, the investigators cover costs, and results are not shared. Gene Tests, available at www.genetests.org, offers details on more than 450 labs that do testing for more than 750 hereditary disorders. Types of genetic testing-

• Carrier testing
• Newborn testing
• Diagnostic testing
• Pre-natal testing

While paternity testing employs DNA markers to determine inheritance patterns between related individuals, forensic testing analyzes DNA sequences to identify persons for legal purposes. While research testing finds undiscovered genes and enhances our understanding of genetic diseases, genetic DNA tests are used to determine ancestry or ethnic background. Usually, patients and medical professionals need access to the results of these examinations.

Regional Snapshot

North America dominates the genetic testing market. The market for genetic testing in North America is expanding due to several causes, including the tendency toward personalized care, attractive reimbursement regulations, and the high frequency of genetic illnesses. Leading firms like 23andMe and AncestryDNA are pushing innovation in genetic research and technology breakthroughs, placing the area at the forefront. Another growing trend is direct-to-consumer genetic testing, which enables anyone to obtain testing services without consulting medical professionals. The genetic testing market in North America is a vibrant and expanding field.

• One of the leading genetic testing brands, Progenesis, entered the Indian market in December 2023. The company started its first genetic laboratory in Delhi and a data center based on AI & Bioinformatics. Not only will it boost the market growth of North America, but it will also grow in the Asia-Pacific region.

Asia-Pacific is expected to grow at the fastest rate in the genetic testing market. The rising population, increasing chronic conditions, and awareness about genetic testing are boosting the growth of the genetic testing market in the Asia-Pacific region.

• Professor Dennis Lo Yuk-ming, who is from the Chinese University of Hong Kong, along with Prenetics, launched a venture called Insighta worth US$ 200 million. The blood tests conducted in this venture will help in detecting cancer cells. In the testing process, the genetic material of the cancerous cells will be identified.

Genetic Testing Market Report Scope

Market Dynamics

Drivers

New technology

PCR is a technology that amplifies DNA, producing several copies from a tiny sample, allowing the measurement or identification of particular genes or areas. It is frequently used to find genetic variants linked to hereditary disorders or diseases like cancer. The order of bases in DNA can be ascertained by DNA sequencing, which aids medical professionals in identifying genes or gene-regulating regions associated with diseases.

The gold standard for clinical DNA sequencing is Sanger sequencing, but it can only read a single, brief piece from a single patient at a time. Next-generation sequencing (NGS) technologies are faster and can analyze the whole exome or genome since they analyze millions of tiny DNA fragments at once. Microarray testing uses synthetic DNA sequences to detect DNA changes, examining chromosomes and SNPs, and is recommended for individuals with developmental delays, intellectual disabilities, autism spectrum disorders, or multiple congenital disabilities.

Recently, researchers from MGH, BWH, MIT, and Harvard have developed a non-invasive genetic test that can screen pregnant individuals' blood for fetal DNA sequence variants. The continuous technological advancements positively impact the growth of the genetic testing market.

Direct-to-consumer genetic testing

A standard genetic testing method is direct-to-consumer (DTC) testing, which provides accessibility, ease of use, and health information without requiring a medical professional. It is available to those who need easy access and can be obtained over the counter or online. DTC tests can offer insights into genetic predispositions to health disorders and metabolism to optimize health and wellness. However, there are issues with data security, privacy, and accuracy; if the results are unexpected or problematic, there may be psychological anguish or anxiety.

Restraints

Ethical and social considerations

The complicated procedure of genetic testing necessitates societal and ethical considerations. A few of the main issues are genetic prejudice, informed consent, privacy, secrecy, family dynamics, psychological effects, equity, regulation, and education. Genetic data is delicate and can disclose private information that may influence access to healthcare, insurance coverage, and work opportunities. Questions concerning how to handle genetic information sharing within families are brought up. Respecting people's rights requires moral supervision and regulation. Making educated decisions requires raising knowledge among the public, legislators, and healthcare professionals. All these factors can hinder the growth of the genetic testing market.

Interoperability and data sharing

Due to issues including a lack of standards, worries about data security, difficulties with regulations and the law, a fragmented data environment, financial and resource limitations, a lack of incentives, and patient permission and control, the genetic testing market has difficulties with interoperability and data sharing. Standardized procedures and formats can make data integration difficult, yet patient privacy depends on data security safeguards. Uncertainties in the law and regulations might also be obstacles. Resolving these issues is essential to successfully exchanging data in the genetic testing market.

Opportunity

Research collaboration

In the fields of genetic testing and customized treatment, research collaboration is essential. It includes resource sharing, data harmonization, clinical trials, cross-disciplinary cooperation, international partnership, ethical issues, and translation of research findings. This facilitates a more thorough understanding of the genetic components of health and disease. Innovative solutions can arise from interdisciplinary collaboration in genetics, bioinformatics, medicine, and ethics. Extensive clinical studies are necessary to assess novel genetic diagnostics and therapies. Transnational genetic data exchange requires careful ethical considerations.

Recent Developments

• In January 2024, the National Health Service (NHS) took a new test for ‘blood matching.’ It's the first personalized healthcare testing for patients who are diagnosed with sickle cell disorder and thalassemia. Around 18,000 people will benefit from this as it will provide more accurate information about blood transfusions and reduce the side effects that can occur due to it.
• In Nov 2023, New CRISPR systems identified rare DNA-cutting genes and enzymes, offering the potential for genome editing by analyzing hundreds of millions of genetic sequences.
• In April 2023, A new gene editing method using cell-penetrating peptides could revolutionize the next generation of cell and gene therapies.
• In March 2022, Researchers at the Garvan Institute of Medical Research developed a DNA test that can quickly and accurately identify various neurological and neuromuscular genetic diseases.

Key Market Players

• Genentech Inc.
• Sorenson Genomics, LLC
• Abbott Molecular
• Bayer Diagnostics
• Biocartis
• BioHelix
• Celera Genomics
• Genomic Health
• HTG Molecular Diagnostics
• PacBio

Market Segmentation

By Test Type

• Carrier Testing
• Predictive Testing
• Diagnostic Testing
• Prenatal & Newborn Testing
• Nutrigenomics
• Pharmacogenomics
• Others

By Disease

• Cancer
• Alzheimer’s
• Thalassemia
• Cystic Fibrosis
• Huntington’s Disease
• Duchenne Muscular Dystrophy
• Other Diseases

Buy this Research Report@ https://www.precedenceresearch.com/checkout/1389

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 650 460 3308